<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01111630</url>
  </required_header>
  <id_info>
    <org_study_id>CWP_RCM_R01</org_study_id>
    <nct_id>NCT01111630</nct_id>
  </id_info>
  <brief_title>Study of Erythropoietin (EPO) Administration Schedule</brief_title>
  <official_title>Compare the Hemoglobin and Hematocrit Variability Between Once &amp; Three Times Weekly Erythropoietin Therapy for the Anemia in Patients With Maintenance Dialysis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>JW Pharmaceutical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>JW Pharmaceutical</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the hemoglobin and hematocrit variability between
      once and three times weekly erythropoietin therapy for the anemia in patients with
      maintenance dialysis.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2009</start_date>
  <completion_date type="Actual">January 2014</completion_date>
  <primary_completion_date type="Actual">October 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The hemoglobin variability between once &amp; three times weekly administration</measure>
    <time_frame>24 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The hematocrit variability between once &amp; three times weekly administration</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean value of Hb and Hct between once &amp; three times weekly administration</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Drop out rate during dose fix period</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean value of Hb and Hct during dose fix period</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Variability of Hb and Hct during dose fix period</measure>
    <time_frame>24weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Weekly oetin-beta maintenance dose between once &amp; three times weekly administration</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Chronic Renal Failure</condition>
  <condition>Anaemia</condition>
  <arm_group>
    <arm_group_label>once weekly</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>three times weekly</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>recomon (Epoetin Beta)</intervention_name>
    <description>administer once weekly</description>
    <arm_group_label>once weekly</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>recomon (Epoetin Beta)</intervention_name>
    <description>administer three times weekly</description>
    <arm_group_label>three times weekly</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients aged between 18 and 80.

          -  Dialysis for at least 3 months.

          -  Epoetin treatment for the last 3 months.

          -  Baseline hemoglobin (Hb) value of &gt;= 9.0 g/dL and &lt; 13.0 g/dL.

          -  Baseline mean weekly epoetin maintenance dose â‰¤ 12,000 IU

          -  Patients who agree to participate in this study in writing.

        Exclusion Criteria:

          -  Hemoglobinopathies, i.e. sickle cell disease, thalassemia of all types.

          -  Hemolysis as defined

          -  Gastrointestinal bleeding necessitating treatment (medication, transfusion) within the
             last 3 months.

          -  Patients with uncontrolled hypertension.

          -  Acute infection of unstable systemic inflammatory disease.

          -  Current malignant disease.

          -  High likelihood of early withdrawal or interruption of the study (e.g. severe diseases
             within the last 3 months, such as myocardial infarction, unstable angina, stroke, deep
             venous thrombosis).

          -  Life expectancy below 12 months.

          -  Planned elective surgery during the study period.

          -  Blood transfusions within the last 3 months.

          -  Pregnancy and lactation.

          -  Other conditions regarded as unsuitability by investigator.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>SugKyun Shin, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>NHIC Ilsan hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>NHIC Ilsan Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 25, 2010</study_first_submitted>
  <study_first_submitted_qc>April 26, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 27, 2010</study_first_posted>
  <last_update_submitted>May 12, 2014</last_update_submitted>
  <last_update_submitted_qc>May 12, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 14, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>chronic renal failure</keyword>
  <keyword>Anaemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia</mesh_term>
    <mesh_term>Renal Insufficiency</mesh_term>
    <mesh_term>Kidney Failure, Chronic</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epoetin Alfa</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

